Angiogenesis and current antiangiogenic strategies for the treatment of cancer

Rahmi Oklu; Thomas G. Walker; Stephan Wicky; Robin Hesketh

doi:10.1016/j.jvir.2010.08.009

Angiogenesis and current antiangiogenic strategies for the treatment of cancer

Rahmi Oklu, Thomas G. Walker, Stephan Wicky, Robin Hesketh

Diagnostic Radiology

Research output: Contribution to journal › Article › peer-review

58 Scopus citations

Abstract

Angiogenesis is a complex process critical for embryonic development and for survival. It is also a critical player in many pathologic processes, most notably in neoplasia. The cell signaling pathways involved in angiogenesis have become key targets for drug design, with more than 2,500 clinical trials currently under way. This review summarizes the essential features of angiogenesis and discusses therapeutic strategies that have been applied to specific diseases known to be associated with perturbation of normal angiogenic control.

Original language	English (US)
Pages (from-to)	1791-1805
Number of pages	15
Journal	Journal of Vascular and Interventional Radiology
Volume	21
Issue number	12
DOIs	https://doi.org/10.1016/j.jvir.2010.08.009
State	Published - Dec 2010

Keywords

Abbreviations
BFGF
Basic fibroblast growth factor
DLL4
ERK
Extracellular signalregulated kinase
FDA
Food and Drug Administration
HIF
Hypoxia-inducible factor
MAPK
MMP
Matrix metalloproteinase
Mitogen-activated protein kinase
Notch ligand delta-like 4

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jvir.2010.08.009

Cite this

@article{07fcc956d1d14a0ca9a066f3be58511a,

title = "Angiogenesis and current antiangiogenic strategies for the treatment of cancer",

abstract = "Angiogenesis is a complex process critical for embryonic development and for survival. It is also a critical player in many pathologic processes, most notably in neoplasia. The cell signaling pathways involved in angiogenesis have become key targets for drug design, with more than 2,500 clinical trials currently under way. This review summarizes the essential features of angiogenesis and discusses therapeutic strategies that have been applied to specific diseases known to be associated with perturbation of normal angiogenic control.",

keywords = "Abbreviations, BFGF, Basic fibroblast growth factor, DLL4, ERK, Extracellular signalregulated kinase, FDA, Food and Drug Administration, HIF, Hypoxia-inducible factor, MAPK, MMP, Matrix metalloproteinase, Mitogen-activated protein kinase, Notch ligand delta-like 4",

author = "Rahmi Oklu and Walker, {Thomas G.} and Stephan Wicky and Robin Hesketh",

year = "2010",

month = dec,

doi = "10.1016/j.jvir.2010.08.009",

language = "English (US)",

volume = "21",

pages = "1791--1805",

journal = "Journal of Vascular and Interventional Radiology",

issn = "1051-0443",

publisher = "Elsevier Inc.",

number = "12",

}

TY - JOUR

T1 - Angiogenesis and current antiangiogenic strategies for the treatment of cancer

AU - Oklu, Rahmi

AU - Walker, Thomas G.

AU - Wicky, Stephan

AU - Hesketh, Robin

PY - 2010/12

Y1 - 2010/12

N2 - Angiogenesis is a complex process critical for embryonic development and for survival. It is also a critical player in many pathologic processes, most notably in neoplasia. The cell signaling pathways involved in angiogenesis have become key targets for drug design, with more than 2,500 clinical trials currently under way. This review summarizes the essential features of angiogenesis and discusses therapeutic strategies that have been applied to specific diseases known to be associated with perturbation of normal angiogenic control.

AB - Angiogenesis is a complex process critical for embryonic development and for survival. It is also a critical player in many pathologic processes, most notably in neoplasia. The cell signaling pathways involved in angiogenesis have become key targets for drug design, with more than 2,500 clinical trials currently under way. This review summarizes the essential features of angiogenesis and discusses therapeutic strategies that have been applied to specific diseases known to be associated with perturbation of normal angiogenic control.

KW - Abbreviations

KW - BFGF

KW - Basic fibroblast growth factor

KW - DLL4

KW - ERK

KW - Extracellular signalregulated kinase

KW - FDA

KW - Food and Drug Administration

KW - HIF

KW - Hypoxia-inducible factor

KW - MAPK

KW - MMP

KW - Matrix metalloproteinase

KW - Mitogen-activated protein kinase

KW - Notch ligand delta-like 4

UR - http://www.scopus.com/inward/record.url?scp=78649493936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649493936&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2010.08.009

DO - 10.1016/j.jvir.2010.08.009

M3 - Article

C2 - 20980167

AN - SCOPUS:78649493936

SN - 1051-0443

VL - 21

SP - 1791

EP - 1805

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

IS - 12

ER -

Angiogenesis and current antiangiogenic strategies for the treatment of cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this